3 results
This is an open, non comparative, multicentre phase II trial, to evaluate the efficacy and feasibility of a newsequential combination of HD-MTX-AraC-based chemoimmunotherapy, followed by R-ICE regimen, and byhigh-dose chemotherapy supported by ASCT.
Primary objective:- To evaluate the safety and tolerability of single ascending doses of ASP3652 in healthy young Caucasian male and female subjectsSecondary objectives:- Different pharmacokinetic outcomes- Different pharmacodynamic outcomes
To study the underlying demographic, clinical and pharmacogenetic factors contributing to the failure of achieving analgesia and/or the occurrence of dose-limiting side effects in individual cancer patients for seperate opioids;- To study if theā¦